Let me make sure I understand this. CLVS is to be sold for $75 - $100 but is selling for $36+ and currently down 3% in spite of the Wall Street 'rumor'. Is it safe to conclude that the 'rumor' was started by you in the futile attempt to influence the stock price. Always remember this.....stock price always trumps any fabricated 'rumor' when it comes to investing. Until CLVS's drugs prove successful via trials, the stock will go no where. cheers
Revenues driven by recent contracts for the most advanced life saving diagnostics will expand 150 times in the next 24 months. And that is just the beginning!
Millennium Healthcare (MHCC) recently announced newly SIGNED contracts with ACO’s IPA’s and MSO’s to provide exclusive, state-of-the-art, non-invasive cardiovascular and cancer diagnostics to 1,300 locations that will escalate Millennium’s current revenues of $2 million per year to over $300 million per year.
Cardiovascular and cancer diagnostics rolling out to physician’s offices this year.
Revenues will begin rapid growth by year end.
Market size for Millennium Diagnostics is 35,000 primary care offices. The first 1,300 recently contracted with Millennium and the rest are standing in line to sign up with Millennium because:
§ Millenniums program increases physician’s revenues dramatically
§ Millennium’s diagnostics are fully paid by Medicare and are free to patients
§ Millennium’s diagnostics appeal to patients because they are life-saving, fast, painless and highly accurate
§ Millennium’s diagnostics are exclusive from Millennium only
§ The physician pays no up front capital costs
Millennium’s market cap is under $40 million today and shares are selling at under $1.00.
What will this growth do to the price of MHCC shares?
Millennium HealthCare is well positioned for explosive growth that is rarely seen.
Sentiment: Strong Buy
It's a shame that Wall Street/investors don't share Barron's enthusiasm. Hopefully they are ahead of the curve. cheers
Clovis (rated at Outperform, $100 target price) is currently not an earnings-driven story. The spotlight remains on CO-1686 as a treatment for first-line epidermal growth factor receptor mutations (EGFRm+) and second-line EGFRm-T790M+ non-small cell lung cancer (NSCLC). Patient identifiable (PI) data presented at the American Society of Clinical Oncology (ASCO) meeting showed that CO-1686 and [AstraZeneca's (AZN)] AZD9291's efficacy was highly comparable. Safety was the key focus with the street positioning AZD9291 having a cleaner safety profile than CO-1686. The call may provide management to expand the insulin-like growth factor 1 receptor (IGF1R) hypothesis. We anticipate additional attention on: 1) updates on Lucitinib phase II trials in advanced breast cancer (FGFR1-amp, 11q-amp, FGF-WT) and squamous NSCLC (FGFR1-amp); 2) updates on ARIEL2 phase II biomarker trial and ARIEL3 phase III trial both for Rucaparib in platinum-sensitive, relapsed ovarian cancer.
Wow...I'm assuming you were delirious when you composed the above post this morning. Stock is being battered and actually fell from $90+ to $40 in less than 60 days BEFORE Yellen spoke.
"this will move higher today".....guess Ms Yellen isn't the only one who doesn't know"biotech etc. or stocks". cheers
most amazing nonsense i have seen in a long time….what the flick does that dix brain know about biotech etc.or stocks for that matter.SHUT YOUR MOUTH U DUMB KLUNT,AND DO YOUR JOB,WHICH IS NOT BEING A STOCK GURU.
Honey, go back to bed, 5-year old kids should not be posting on the Yahoo! boards about Daddy's company
Sorry but the jury is out on whether the drugs are 'excellent'. The primary trial results were less than stellar a few weeks ago.....hence the dramatic stock decline. However if future trial results end up to be 'excellent' then the stock will soar. If there are more disappointments in store....Katie bar the door. cheers